The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is the impact of bridging therapy on the outcomes of patients receiving CAR T therapy?

Dec 12, 2019

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Michael Jain, Moffitt Cancer Center, Tampa, US. We asked: What is the impact of bridging therapy on the outcomes of patients receiving CAR T therapy?

Michal Jain talks about the rationale behind the study looking to improve outcomes for patients with relapsed or refractory lymphoma undergoing CAR T cell therapy by using bridging therapy. He also summarises the study results.

What is the impact of bridging therapy on the outcomes of patients receiving CAR T therapy?